nce patients with non-valvular atrial fibrillation (NVAF) develop cardioembolic stroke, the neurological symptoms are often severe and outcome is poor. Prevention of cardioembolic stroke is, therefore, important in those with NVAF, and warfarin for those with a CHADS2 score ≥2 is recommended and for those with a CHADS2 score of 1 it may be considered, according to the 2008 guideline of the Japanese Circulation Society for the management of AF. 1 However, underuse of warfarin has become a big issue worldwide. Although the efficacy of warfarin for the prevention of stroke in NVAF patients is well established, many patients with NVAF who would benefit from warfarin treatment do not receive it. A systemic review indicated increasing age, increasing bleeding risk, previous bleeds, falls risk, comorbidities and ability to comply with warfarin therapy as factors influencing attitudes of physicians regarding warfarin therapy. 2 In Japan, detailed analysis of the non-use of warfarin has not been performed.
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In this issue of the Journal, J-RHYTHM Registry Investigators investigate the determinants of warfarin use and anticoagulation levels in patients with AF who were registered in the J-RHYTHM Registry, 3,4 and found that 88.8% of 6,324 patients with NVAF and CHADS2 score ≥2 were receiving warfarin, that determinants of warfarin use were age ≥60 years, type of AF (persistent or permanent), and comorbidities (congestive heart failure, diabetes mellitus, prior stroke or TIA) and that warfarin was not likely to be administered to patients who were younger than 60 years, had paroxysmal AF or were receiving antiplatelet drugs. I think that the high rate of 88.8% in prescribing warfarin and the determinants of warfarin therapy, including comorbidities such as congestive heart failure, diabetes mellitus, and stroke or TIA, obviously indicated good adherence of Japanese cardiologists to the 2008 Japanese guideline for the management of AF. 1 On the other hand, it was disappointing that paroxysmal AF and administration of antiplatelets were still negative determinants. In 2004, an observational study performed in Japan already indicated that paroxysmal AF was associated with non-use of warfarin in NVAF patients with CHADS2 ≥1. 5 The thromboembolic risk between paroxysmal and chronic AF was investigated in Japan and Western countries and reported to be similar 6-8 (Table) . Moreover, it should be emphasized that patients with paroxysmal AF could develop major stroke with poor outcome unless appropriate anticoagulant therapy is performed. However, it may be an issue to address that characteristics such as frequency and duration, which may be associated with cardioembolic stroke, in paroxysmal AF have not been fully elucidated. Study focusing on the relation between such characteristics and the incidence of cardioembolic stroke in paroxysmal AF may be needed.
Meta-analysis 9 has clearly demonstrated that anticoagulant therapy is superior to antiplatelet therapy in preventing thromboembolism, with a relative risk reduction of 37%. It also showed that antiplatelet therapy was significantly better than placebo or control, with a relative risk reduction of 22%. However, we need to pay attention to the stroke mechanism that 
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antiplatelets may prevent. A subanalysis of the Stroke Prevention in Atrial Fibrillation Study indicated that antiplatelets prevented non-cardioembolic stroke, but not cardioembolic stroke, in patients with AF. 10 It was reported in 2006 that aspirin was not effective in preventing ischemic cerebrovascular events in Japanese patients with NVAF at low risk for stroke or systemic embolism. 11 When we consider antiplatelet therapy in patients with NVAF, we had better take into account that anticoagulation is superior to antiplatelet therapy, and that antiplatelet drugs may prevent non-cardioembolic stroke in NVAF patients, but cannot prevent cardioembolic stroke, a major disabling stroke with poor outcome. According to observational studies, in which major ischemic or hemorrhagic events occurred often at INR levels below 1.6 or above 2.6, respectively, in elderly NVAF patients with a past history of cardioembolic stroke. 12, 13 Japanese guidelines recommend INR levels between 1.6 and 2.6 for elderly patients aged 70 years or more with NVAF and between 2.0 and 3.0 for patients younger than 70 years. 1 However, the current study demonstrated that lower INR levels than the target level were likely to be displayed by patients younger than 60 years. Because once a young patient with NVAF develops cardioembolic stroke, the patient and his or her family will have a big burden for many years, good adherence to the target INR between 2.0 and 3.0 in patients younger than 70 years is required.
